Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.

alprazolam

Adjunctive therapy

Brands: XANAX, XANAX XR

Published 2026-03-24 · Last reviewed 2026-03-31 · 4 references

Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.

Print sheet Review evidence

At a glance

Class: Adjunctive therapy·Typical dose: Dosing is typically kept at the lowest effective dose for the shortest feasible duration; dose escalation without a clear target symptom and reassessment plan is avoided.·Half-life: Single-dose mean 11.2 h; Single-dose range 6.3–26.9 h·LAI available: No

Class: Adjunctive therapy
Typical dose: Dosing is typically kept at the lowest effective dose for the shortest feasible duration; dose escalation without a clear target symptom and reassessment plan is avoided.
Half-life: Single-dose mean 11.2 h; Single-dose range 6.3–26.9 h
LAI available: No

Quick answers

What is alprazolam?: Alprazolam (brand Xanax; Xanax XR) is a high-potency benzodiazepine approved for anxiety disorder and panic disorder, often providing rapid relief of intense anxiety symptoms. Because it is potent and relatively short acting, it has higher reinforcement, dependence, and withdrawal risk than many alternatives and should not be treated as a default long-term strategy.
What is XANAX?: XANAX is a brand name for alprazolam (other brands: XANAX XR).
What is XANAX (alprazolam) used for?: Label indications include: Anxiety disorder and panic disorder (label).
What drug class is XANAX (alprazolam)?: Benzodiazepine.
What is the mechanism of action of XANAX (alprazolam)?: Benzodiazepine; positive allosteric modulator of GABA-A receptors.
What strengths does XANAX (alprazolam) come in?: Immediate-release tablets and extended-release tablets/capsules are available; strengths vary by product.

General information

Alprazolam is a high-potency benzodiazepine approved for anxiety disorder and panic disorder, often providing rapid relief of intense anxiety symptoms. Because it is potent and relatively short acting, it has higher reinforcement, dependence, and withdrawal risk than many alternatives and should not be treated as a default long-term strategy.

Shorter half-life and higher potency can lead to interdose withdrawal, rebound anxiety, and difficult tapers—especially with chronic use.

Because of dependence and withdrawal risk, alprazolam is commonly used for targeted, time-limited situations (for example, a brief bridge while psychotherapy and SSRI/SNRI plans ramp up) with explicit functional goals, limited quantities, and a written taper/stop plan from day one.

The alprazolam compare view, the alprazolam evidence feed, and the alprazolam print page can support shared planning for short-term symptom relief and a safer long-term strategy.

U.S. approvals

Anxiety disorder
Panic disorder

Formulations & strengths

Immediate-release tablets and extended-release tablets/capsules are available; strengths vary by product.

Generic availability

Widely available generically.

Because alprazolam is potent and relatively short acting, many clinicians use it in targeted, time-limited roles with explicit taper plans and frequent reassessment. Short prescriptions and a defined stop date help reduce drift into open-ended chronic use and lower the risk of interdose withdrawal.

View labelExact

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

Positive allosteric modulator of GABA-A receptors that increases inhibitory neurotransmission.

Rapid onset and high potency can reinforce use and increase dependence risk relative to some alternatives.

Like other benzodiazepines, alprazolam treats symptoms but does not address underlying anxiety drivers; pair with psychotherapy and SSRI/SNRI-based plans when ongoing anxiety is present.

GABA-A receptor facilitation (benzodiazepine class).

Metabolism & pharmacokinetics

Extensively metabolized primarily by CYP3A4 (label).
Mean elimination half-life ~11.2 hours (range ~6.3–26.9 hours) in healthy adults (label).
Exposure increases with CYP3A inhibitors and in hepatic impairment (label).
Clinically significant interactions occur with strong CYP3A inhibitors (e.g., azole antifungals, macrolides, ritonavir) and inducers (e.g., carbamazepine, rifampin); reassess sedation, withdrawal, and symptom control when interacting drugs are started or stopped.

Dosing & administration

Dosing is typically kept at the lowest effective dose for the shortest feasible duration; dose escalation without a clear target symptom and reassessment plan is avoided.
For courses beyond a few weeks, clinicians typically taper gradually; abrupt discontinuation increases withdrawal and seizure risk.
Alprazolam is generally not used as a nightly sleep medication; if insomnia is the primary complaint, clinicians often focus on underlying drivers and insomnia-specific strategies instead.
Extended-release products should not be crushed or split, and additional “as needed” redosing on top of scheduled dosing can increase dependence and adverse effects.

Monitoring & labs

Functional benefit and safety should be reassessed at each renewal; avoid open-ended continuation without documented goals.
Substance use screening and prescription monitoring review are commonly used; a single prescriber and pharmacy plan can reduce misuse risk.
Monitor sedation, falls, and driving impairment—especially in older adults and when other CNS depressants are present.
If discontinuing after more than brief use, taper gradually and monitor for withdrawal symptoms and rebound anxiety.

Sources: FDA/DailyMed label; guideline statements.

Adverse effects

FDA boxed warnings

Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death.

Common side effects (≥10%)

Sedation / psychomotor slowing: Assess fall risk and ability to drive or operate machinery.
Cognitive impairment / amnesia: Dose-dependent; higher risk in older adults.
Rebound anxiety / interdose withdrawal: More likely with short-acting agents and chronic use; avoid frequent redosing and plan structured tapers when discontinuing.
Dizziness: Increased fall risk, especially with other sedatives.
Fatigue: Can impair daytime function and reinforce dose escalation patterns.

Other notable effects

Dependence, tolerance, and withdrawal symptoms after chronic use—requires tapering plans.
Paradoxical agitation or disinhibition in susceptible individuals.
Respiratory depression risk increases with sleep apnea, COPD, alcohol, or sedating co-prescriptions.
Falls, delirium, and functional impairment are more likely in older adults and with polypharmacy; consider alternatives and reassess benefit vs risk frequently.

Interactions

Additive CNS and respiratory depression with opioids, alcohol, antihistamines, and sedating antipsychotics.
Strong CYP3A inhibitors (e.g., azoles, macrolides, ritonavir) can markedly increase exposure; CYP3A inducers (e.g., carbamazepine, rifampin) may reduce efficacy and destabilize symptoms—monitor closely and consider alternatives.
Combining with other sedative-hypnotics (including Z-drugs) and alcohol increases sedation and overdose risk; avoidance is preferred when possible, and a single prescriber/pharmacy approach can reduce misuse risk.

Other useful information

Clinicians typically document indication, time horizon, and taper plan at initiation and reassess necessity frequently.
Review prescription monitoring data and screen for substance use disorders when benzodiazepines are used.
For chronic anxiety and panic disorder, psychotherapy and SSRI/SNRI-based plans are typically the backbone; benzodiazepines are usually reserved for short-term targeted roles.
Short prescriptions with planned follow-up and no “automatic” refills help prevent drift into chronic use; when discontinuing, taper gradually and monitor for withdrawal symptoms (anxiety, insomnia, tremor) and rare seizure risk.

References

Related hubs:SMI toolkit·Support resources